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Clinical Summary
A 43-year-old woman was urgently admitted to the hospital
because of a syncopal episode. In the past she had had repeated
spontaneous abortions, venous thrombotic events during preg-
nancy, and thrombocytopenia associated with lupus anticoagu-
lant positivity. A diagnosis of antiphospholipid syndrome
(APS) had been suggested 14 years earlier. Results of cardiac
physical examination and a 12-lead electrocardiogram were
unremarkable. Two-dimensional transthoracic and transesoph-
ageal echocardiography showed ventricular and left atrial
chambers normal in size and function, whereas a polypus,
mobile mass attached to the free wall was visualized in the right
atrium (Figure 1, A and B ). Semilunar and atrioventricular
valves were normal, without any evidence of vegetations. The
patient underwent surgical removal of the mass, and pathologic
examination ruled out a neoplastic or infective nature, by show-
ing a fibrin network entrapping blood cells with calcific deposits
at its implantation base (Figure 2). The histologic features were
in keeping with an organized thrombosis, and a diagnosis of
nonbacterial thrombotic endocarditis of the right atrial endo-
cardium in the setting of APS was suggested. At 6 months’
follow-up, the patient is doing well with long-term anticoagu-
lant therapy. She has no evidence of intracardiac mass recur-
rence on 2-dimensional echocardiography (Figure 1, C ).
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Figure 1. A and B, Two-dimensional transesophageal echocardiogram shows a polypus mass in the right atrium
attached to the free wall and free floating during the cardiac cycle so as to occasionally impinge into the tricuspid
valve orifice. C, No evidence of intra-atrial mass recurrence at 2-dimensional transthoracic echocardiography at
6 months’ follow-up.
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Discussion
APS is defined according to the clinical and laboratory criteria
established by an international consensus, that is, history of throm-
bosis and/or pregnancy morbidity, associated with the presence in
the blood of lupus anticoagulants and/or anticardiolipin antibodies
of immunoglobulin G and/or immunoglobulin M isotype, positive
in medium or high titers on 2 or more occasions at least 6 weeks
apart.1 APS usually is classified as primary and secondary, respec-
tively, accordingly to the absence or presence of an underlying
disease as well as other autoimmune, malignancy, or drug-induced
disorders. In both instances, every organ can be involved by
thrombotic events. In a recent study of a cohort of 1000 patients
affected by primary and secondary APS, cardiac involvement was
observed in 27% of cases,2 mostly characterized by valvular and
coronary artery disease. The most frequent echocardiographic
findings are either valve vegetations or leaflets thickening. The
literature reports only a few cases of intracardiac thrombosis3
associated with primary APS, observed in all cardiac chambers,
provoking either pulmonary or systemic embolism.
The clinical history, along with the stoppage of anticoagulant
therapy for many years, led to a diagnosis of atrial thrombosis. The
treatment of patients affected by APS is usually based on a healthy
life-style, by abstaining from smoking and intake of oral contra-
ceptives, by reducing the risk for vein stasis and vascular injuries,
and by performing thromboprophylaxis during pregnancy. More-
over, in patients who have already experienced thrombotic events,
it is mandatory to prevent recurrent thrombosis by intermediate to
high-intensity warfarin therapy.4 Whether thrombolysis, with a
high-intensity anticoagulation protocol based on warfarin, or a
surgical excision is the better first therapeutic approach remains
unknown. However, the great size of the mass and the free-floating
appearance at 2-dimensional echocardiogram, which seemed at
high risk for pulmonary embolism, led us to choose surgical
therapy. Moreover, the pathologic features of an organized throm-
bosis with early calcific deposits, which could constitute the nu-
cleus for further thrombus deposition, further support the surgical
approach.
Since relapsing thrombosis has been reported in both the arte-
rial and venous bed despite long-term warfarin treatment, a strict
follow-up by 2-dimensional echocardiogram should be recom-
mended in patients affected by APS syndrome.
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Figure 2. A, Gross examination of the resected mass reveals a
reddish elongated neoformation with a rough surface, 3.5 0.8
0.9 cm in size and 2.3 g in weight. B, At histologic examination,
the mass consisted of a fibrin network entrapping red cells,
platelets, and leukocytes with focal early organization into fi-
brous tissue.
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